SCHEMBL24558170

SCHEMBL24558170

COC(=O)c1c(F)c(Cl)cc2ncn(C)c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.37
DPP8 Q6V1X1 1/20 0.37
NOTUM Q6P988 1/20 0.36
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRE P78334 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31107272 0.84 DPP4 (0.39) DPP4DPP8NOTUMALDH1A1POLB
SCHEMBL21986819 0.80 KDM4E (0.42) DPP4DPP8NOTUMALDH1A1KDM4E
SCHEMBL30158927 0.74 POLB (0.48) ALDH1A1KDM4EHPGDDYRK1APOLB
SCHEMBL21986867 0.72 KDM4E (0.40) DPP4DPP8NOTUMALDH1A1KDM4E
SCHEMBL21986726 0.71 DPP4 (0.43) DPP4KDM4ETSHRPDE4APDE4B
SCHEMBL2936419 0.71 NQO2 (0.42) DPP4DPP8KDM4ETSHRPDE4A
SCHEMBL21986901 0.70 KDM4E (0.39) DPP4ALDH1A1KDM4EHPGDTSHR
SCHEMBL22778007 0.69 L3MBTL1 (0.45) ALDH1A1KDM4ETSHRPOLBTP53
SCHEMBL21820497 0.69 ALDH1A1 (0.43) NOTUMALDH1A1KDM4ETSHRHSD17B10
SCHEMBL30159099 0.69 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDTSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113508118-B Fused tricyclic compounds useful as anticancer agents 阿斯利康(瑞典)有限公司 2024-07-19 CN disclosed
EP-3935060-B1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2023-11-15 EP disclosed
US-20220204527-A1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA UK LIMITED (GB) 2022-06-30 US disclosed
CN-113508118-A Fused tricyclic compounds useful as anticancer agents 阿斯利康(瑞典)有限公司 2021-10-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204527-A1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS MCL1, TP53, CCNA2 DPP4 4131/4885DPP8 3092/4885NOTUM 3077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.